Learn more about NBS 6 for Depression Therapy
Indications for use
Depression
Nexstim's noninvasive NBS 6 is cleared by the Food and Drug Administration (FDA, K171902 & K182700). Nexstim NBS 6 is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
CE mark: Nexstim NBS 6 for depression is intended to be used for treatment of major depressive disorder (MDD) by targeting and delivering noninvasive repetitive TMS stimulation to the patient's dorsolateral prefrontal cortex.
Pain
The Nexstim NBS 6 is not cleared by the FDA for commercial use of the treatment of chronic pain in the United States, for investigational use only.
CE mark Intended purpose
In adult patients suffering from chronic unilateral neuropathic pain, Nexstim NBS 6 is intended to provide electric field navigated noninvasive repetitive TMS stimulation as therapy to alleviate pain. Nexstim NBS 6 is intended to be used by trained clinical professionals.
CE mark Indications for use
Nexstim NBS 6 is indicated for MRI-guided and electric field (or E-field) navigated, noninvasive repetitive TMS stimulation (rTMS) of the motor cortex as therapy to alleviate chronic unilateral neuropathic pain in adult patients. Nexstim NBS 6 is intended to be used by trained clinical professionals.
Interested in a live demo of the NBS 6?
Our team of physicians, researchers, and engineers is prepared to answer your questions. If you would like to learn more or set up a virtual demonstration for your team, please contact us at info@nexstim.com